文献速递乳腺癌放疗胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗

REQUITE前瞻性多中心队列:乳腺癌、肺癌与前列腺癌放疗患者资源库

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer.
PubMed 文献 · Radiother Oncol · 2019-05-27

REQUITE是一项国际前瞻性队列研究,在8国26家医院招募乳腺癌、前列腺癌和肺癌接受根治性放疗的患者,目标5300例。研究建立集中数据库与生物样本库,收集医生和患者报告结局、影像、剂量体积直方图、基因型及RILA检测数据,并报告2年(肺癌1年)≥2级CTCAE毒性示例患病率。

要点

  • 实际招募乳腺癌2069例、前列腺癌1808例、肺癌561例,肺癌仅达目标51%。
  • 数据库含医患报告结局、乳腺照片、DICOM、DVH及基因型与RILA数据。
  • 2年≥2级毒性示例:乳腺萎缩13%、前列腺直肠出血3%、肺癌呼吸困难27%。

核心结论

  • 集中数据库与关联生物样本库是验证放疗晚期毒性预测模型和生物标志物的宝贵资源。

研究设计与样本

  • 国际前瞻性队列研究,2014年4月至2017年3月在8国26家医院招募乳腺癌、前列腺癌或肺癌并计划根治性放疗的患者,目标5300例。
  • 放疗方案按当地常规制定,但中心使用标准化数据收集表格,采集治疗前血样,随访至少12个月(肺癌)或24个月(乳腺癌/前列腺癌)。

主要发现

  • 招募乳腺癌2069例(目标的99%)、前列腺癌1808例(86%)、肺癌561例(51%)。
  • 数据库包含医生报告表47,025份、患者报告结局54,901份、乳腺照片11,563张、DICOM 17,107份和DVH 12,684份。
  • 有欧洲血统的4223例患者(乳腺癌1948、前列腺癌1728、肺癌547)具备填补后基因型数据,1319例有RILA检测数据。
  • 中央生物样本库储存DNA 4409份和PAXgene管3039份。
  • 2年(肺癌1年)≥2级CTCAE毒性示例患病率:乳腺萎缩13%、前列腺直肠出血3%、肺癌呼吸困难27%。

临床怎么用

  • 该资源可用于多国验证预测放疗晚期毒性的模型和生物标志物。
  • 标准化收集的医患报告结局、影像与剂量数据支持跨中心比较和放射敏感性研究。

局限性

  • 本文仅提供描述性汇总数据,未报告预测模型验证结果或毒性相关分析。
  • 肺癌实际招募仅达目标的51%,可能影响该癌种代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: REQUITE aimed to establish a resource for multi-national validation of models and biomarkers that predict risk of late toxicity following radiotherapy. The purpose of this article is to provide summary descriptive data. METHODS: An international, prospective cohort study recruited cancer patients in 26 hospitals in eight countries between April 2014 and March 2017. Target recruitment was 5300 patients. Eligible patients had breast, prostate or lung cancer and planned potentially curable radiotherapy. Radiotherapy was prescribed according to local regimens, but centres used standardised data collection forms. Pre-treatment blood samples were collected. Patients were followed for a minimum of 12 (lung) or 24 (breast/prostate) months and summary descriptive statistics were generated. RESULTS: The study recruited 2069 breast (99% of target), 1808 prostate (86%) and 561 lung (51%) cancer patients. The centralised, accessible database includes: physician- (47,025 forms) and patient- (54,901) reported outcomes; 11,563 breast photos; 17,107 DICOMs and 12,684 DVHs. Imputed genotype data are available for 4223 patients with European ancestry (1948 breast, 1728 prostate, 547 lung). Radiation-induced lymphocyte apoptosis (RILA) assay data are available for 1319 patients. DNA (n = 4409) and PAXgene tubes (n = 3039) are stored in the centralised biobank. Example prevalences of 2-year (1-year for lung) grade ≥2 CTCAE toxicities are 13% atrophy (breast), 3% rectal bleeding (prostate) and 27% dyspnoea (lung). CONCLUSION: The comprehensive centralised database and linked biobank is a valuable resource for the radiotherapy community for validating predictive models and biomarkers. PATIENT SUMMARY: Up to half of cancer patients undergo radiation therapy and irradiation of surrounding healthy tissue is unavoidable. Damage to healthy tissue can affect short- and long-term quality-of-life. Not all patients are equally sensitive to radiation "damage" but it is not possible at the moment to identify those who are. REQUITE was established with the aim of trying to understand more about how we could predict radiation sensitivity. The purpose of this paper is to provide an overview and summary of the data and material available. In the REQUITE study 4400 breast, prostate and lung cancer patients filled out questionnaires and donated blood. A large amount of data was collected in the same way. With all these data and samples a database and biobank were created that showed it is possible to collect this kind of information in a standardised way across countries. In the future, our database and linked biobank will be a resource for research and validation of clinical predictors and models of radiation sensitivity. REQUITE will also enable a better understanding of how many people suffer with radiotherapy toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Seibold P, Webb A, Aguado-Barrera ME, et al. REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer. Radiother Oncol. 2019. PMID: 31146072. doi:10.1016/j.radonc.2019.04.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。